公开(公告)号：US4937242A

公开(公告)日：1990-06-26

申请号：US165705

申请日：1988-03-08

申请人： Hiroshi Matsui ,  Fumio Fukata ,  Takayoshi Mori ,  Nobuharu Kakeya ,  Kazuhiko Kitao

发明人： Hiroshi Matsui ,  Fumio Fukata ,  Takayoshi Mori ,  Nobuharu Kakeya ,  Kazuhiko Kitao

IPC分类号： A61K31/4427 ,  A61K31/455 ,  A61K31/55 ,  A61P3/00 ,  A61P9/12 ,  C07D211/90 ,  C07D401/12 ,  C07D405/12

CPC分类号： C07D401/12 ,  C07D211/90 ,  C07D405/12

摘要： 1,4-Dihydropyridine derivatives of the general formula: ##STR1## wherein X.sup.1 and X.sup.2 independently represent hydrogen, fluoromethyl, fluoromethoxy, halogen, cyano, or nitro; R.sup.1 represents a lower alkyl; R.sup.2 represents acyl, alkoxycarbonyl, acylalkyl, an N-alkyl-substituted carbamoylalkyl, alkoxyalkyl, alkoxycarbonylalkyl, acyloxyalkyl, nitratoalkyl, cyanoalkyl, heterocycle-alkyl, haloalkyl, alkenyl, or alkynyl; A represents an alkylene comprising a carbon atom to which 2 alkyls are bonded and having in total at least 5 carbon atoms; m represents the integer 1, 2 or 3; acid addition salts thereof; a method of production thereof; and pharmaceutical compositions containing such compound(s).Such compounds have pharmacological activities, in particular potent and long lasting hypotensive activity, coronary vasodilatation, cerebral vasodilatation, peripheral vasodilatation, renal vasodilatation and platelet aggregation inhibitory activity.

公开(公告)号：US06262108B1

公开(公告)日：2001-07-17

申请号：US09555751

申请日：2000-07-28

申请人： Hiroaki Shirahase ,  Akihisa Yoshimi ,  Shohei Nakamura ,  Mamoru Kanda ,  Fumio Fukata

发明人： Hiroaki Shirahase ,  Akihisa Yoshimi ,  Shohei Nakamura ,  Mamoru Kanda ,  Fumio Fukata

IPC分类号： A61K3135

CPC分类号： C07D311/24 ,  A61K31/352

摘要： The cromoglycic acid compound of the formula (I) has an antirheumatic action, an antiinflammatory action and an immunomodulating action. This compound is effective for the inhibition of the symptoms of chronic rheumatoid arthritis and is associated with fewer side effects. Therefore, the antirheumatic agent of the present invention can be used beneficially for the treatment of rheumatoid arthritis. In addition, this compound has anti-type I and anti-type IV allergic activities. Therefore, the compound can be used beneficially mainly for the treatment of allergic dermatitis, in which a type IV allergic reaction is involved, such as contact dermatitis, in which a type IV allergic reaction is involved, atopic dermatitis, in which type I and type IV allergic reactions are involved and the like.

摘要翻译： 式（I）的色甘酸化合物具有抗风湿作用，抗炎作用和免疫调节作用。 该化合物对于抑制慢性类风湿性关节炎的症状是有效的，并且与副作用较少有关。 因此，本发明的抗风湿剂可有益地用于治疗类风湿性关节炎。 此外，该化合物具有抗I型和抗IV型过敏活性。 因此，该化合物可以有益地用于治疗涉及IV型过敏反应的过敏性皮炎，例如涉及IV型过敏反应的接触性皮炎，特应性皮炎，I型和型 涉及IV过敏反应等。

公开(公告)号：US6149923A

公开(公告)日：2000-11-21

申请号：US202368

申请日：1998-12-10

申请人： Hiroaki Shirahase ,  Akihisa Yoshimi ,  Fumio Fukata ,  Hideki Okunishi ,  Yuta Kobayashi

发明人： Hiroaki Shirahase ,  Akihisa Yoshimi ,  Fumio Fukata ,  Hideki Okunishi ,  Yuta Kobayashi

IPC分类号： A61K31/35 ,  A61K31/352 ,  C07D311/24 ,  C07D311/54 ,  A61K9/00 ,  A01N43/16

CPC分类号： A61K31/352 ,  A61K31/35 ,  C07D311/24 ,  Y10S514/825

摘要： An antirheumatic agent comprising diethyl L-lysylcromoglycate of the following formula ##STR1## or a nontoxic salt thereof as an active ingredient. This compound has an anti-inflammatory action and immunomodulating action, is absorbed by oral administration to be delivered efficiently to local sites, and is associated with fewer side effects, so that it serves well as an antirheumatic agent that can be administered orally.

摘要翻译： PCT No.PCT / JP97 / 01974 Sec。 371 1998年12月10日第 102（e）日期1998年12月10日PCT提交1997年6月6日PCT公布。 第WO97 / 47297号公报 日期：1997年12月18日一种抗风湿剂，其包含下式的L-赖氨酰色甘酸二乙酯或其无毒盐作为活性成分。 该化合物具有抗炎作用和免疫调节作用，通过口服给药被有效地递送至局部位置，并且与副作用较少相关，因此其作为可以口服给药的抗风湿剂起作用。